Funding for this research was provided by:
Gilead Sciences (IN-UK-380-5352)
Received: 6 April 2020
Accepted: 7 July 2020
First Online: 20 July 2020
Ethics approval and consent to participate
: This trial protocol has been approved by the Health Research Authority, UK (19/LO/0905). All patients in the trial will provide written informed consent to participate.
: Not applicable.
: CI has received honoraria, support to attend conferences and research funding (paid to university of Sussex) from Gilead Sciences. DC has received honoraria and support to attend conferences from Gilead Sciences and ViiV. LW has received speaker/advisory fees or conference support from Gilead, ViiV, Janssen, MSD, Cipla and Mylan. CO has been a recipient of grants, speaker’s bureau and travel sponsorship from Gilead, MSD, ViiV, GSK and Janssen. NP has received honoraria for services rendered to Gilead Sciences. AMG receives personal consultancy fees from Roche Pharma, provides consulting services to Gilead Sciences, Janssen, and ViiV (paid to the University of Liverpool) and is the recipient of research funding from Gilead, Roche Pharma, and ViiV (paid to the University of Liverpool). All other authors declare that they have no competing interests.